Aims Midazolam has good anxiolytic qualities and is a well established premedication agent
before anaesthesia or short surgical procedures. The objective of the present study was to …

Whether age and sex influence the depth of sedation and the pharmacokinetics of
midazolam is currently unknown. The influence of age and sex was investigated in 117 …

Critically ill patients often benefit from sedation to optimize their care and their ventilatory
support. Ideally, incremental doses of a drug are administered to produce the desired level …

Aims Midazolam is given intravenously for induction of anaesthesia and conscious sedation
and by subcutaneous infusion in patients in palliative care units. The objective of the present …

One of the most widely used options for minimal/moderate sedation in pediatric patients is
oral midazolam, as it presents an alternative to less well‐accepted routes of administration …

Conclusions The pharmacokinetics of midazolam in our patients showed a shorter half-life,
probably due to the higher hepatic clearance based on the high CI in children, as …

There is no randomized study carried out in order to compare their pharmacokinetic
parameters although midazolam, as a sedative, has been widely administered via …

Midazolam is metabolized by the developmentally regulated intestinal and hepatic drug‐
metabolizing enzyme cytochrome P450 (CYP) 3A4/5. It is frequently administered orally to …

A serum concentration profile study on midazolam in children was done. Fifty six children
aged 3–10 years took part. The routes investigated were intravenous, intramuscular, rectal …

Midazolam (MDZ) is used for sedation in surgical procedures; its clinical effect is related to
its receptor affinity and the dose administered. Therefore, a pharmacokinetic …